Brexit news: UK first to roll out new peanut allergy treatment | Sciences | News

NHS England has reached a deal for a drug that decreases the severity of symptoms, including anaphylaxis. Palforzia, which is administered orally, will be available for up to 600 children aged 4 to 17 the first year and 2,000 the following year.

It will relieve stress for one in 50 children in the UK who have a peanut allergy.

It will also ease the burden on their families – who must constantly worry about eating contaminated food and carrying epinephrine injections to treat a life-threatening allergic reaction.

Stephen Powis, national medical director for NHS England, said the drug would help “reduce the fear and anxiety of patients and their families who may have been living with this allergy for years”.

He added: “This pioneering treatment can change the lives of patients and their families and, thanks to the agreement reached by the NHS, people here will be the first in Europe to benefit from it.”

READ MORE: Archeology’s breakthrough as ‘first evidence’ of ancient tradition

She added, “The treatment we received means that Emily is free from limitations and the fear that even the smallest mistake could be life threatening, and it took away all the tension and worry that just eating weighed on us every day. “

Since the trial, Emily has been able to confidently attend parties, feed the zoo animals and take her first New York vacation, Ms. Pratt said.

She explained that the change “was especially noticeable on special occasions like birthdays, Christmas and holidays where there are often special foods like cakes, ice cream and treats that invariably had warnings,” may contain peanuts “or menus not in English”.

A study from Imperial College London found that of the 187 people who died from anaphylaxis in the UK from 1992 to 2018, at least 86, or 46%, suffered from allergies to peanuts or other tree nuts. .

The news is an example of how the UK has moved ahead of its European counterparts since Brexit.

This notably happened during the coronavirus pandemic, when the vaccine rollout in the UK far exceeded that in the EU for months.

Comments are closed.